The E1A mutant was engineered with a 27-bp deletion in the E1A CR2 region necessary for retinoblastoma (Rb) protein binding to attenuate viral replication and cytolysis in normal quiescent tissues but not in tumor cells [11,12]. This evidence concerns the gene DHTKD1 and neoplasm.